Evolving Treatment Paradigms in HR-Positive, HER2-Negative Breast Cancer: Integrating the Latest Evidence Into Clinical Practice

Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview
Advances in therapy for patients with hormone receptor"positive (HR+)/human epidermal growth factor receptor 2"negative (HER2-) breast cancer have the potential to reduce disease recurrence and risk of mortality. However, the complex and evolving treatment landscape of this cancer poses a challenge to oncology care teams. In this activity, expert faculty will review the latest clinical data for novel targeted therapies in early and metastatic HR+/HER2- breast cancer as well as evidence-based approaches to selecting and sequencing treatment. Interprofessional approaches for reducing disparities and addressing inequities across the breast cancer care continuum will also be discussed.

This enduring activity is a recorded session from Oncology Congress that took place on September 24, 2022.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Select appropriate adjuvant therapy or sequence of therapies for patients with HR+, HER2- early breast cancer
Apply evidence-based strategies to guide personalized treatment planning for patients with metastatic HR+, HER2- breast cancer
Integrate shared decision-making into the management of HR+, HER2- breast cancer to ensure patient goals and preferences are factored into treatment selection
Discuss interprofessional strategies for improving breast cancer care and management in rural and underserved settings